SciClone seals another deal to expand China CV portfolio
This article was originally published in Scrip
The China-focused US firm SciClone Pharmaceuticals has struck its second licensing deal in the cardiovascular sector in as many months, this time acquiring rights from Taiwan Liposome Company (TLC) to a therapy for peripheral arterial disease (PAD) in the Chinese market.
You may also be interested in...
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.